Diagnostics News and Research

RSS

Patient-specific cancer cell lines designed to predict chemotherapy sensitivity

In laboratory studies, scientists at the Johns Hopkins Kimmel Cancer Center have developed a way to personalize chemotherapy drug selection for cancer patients by using cell lines created from their own tumors.

15 Feb 2013

Improving tuberculosis (TB) diagnosis: an interview with Professor Madhukar Pai, MD, PhD

TB is an infectious disease caused by Mycobacterium tuberculosis. Nearly 9 million people develop TB every year, and TB kills nearly 1.4 million individuals each year. While the incidence of TB has steadily declined in the west, it remains a huge public health problem in many developing countries, with India having the highest burden.

15 Feb 2013

Researchers show how gene mutations shift and evolve over time in chronic lymphocytic leukemia

Tumors are not factories for the mass production of identical cancer cells, but are, in reality, patchworks of cells with different patterns of gene mutations. In a new study, researchers at Dana-Farber Cancer Institute and the Broad Institute show, more fully than ever before, how these mutations shift and evolve over time in chronic lymphocytic leukemia (CLL) - providing a strobe-like look at the genetic past, present, and future of CLL tumors.

15 Feb 2013

Castle Biosciences launches MyUvealMelanoma website

Castle Biosciences Inc., a leading developer of prognostic tests for rare cancers, announced today the launch of MyUvealMelanoma.com, a website created to educate newly diagnosed patients, their families and healthcare providers about the most common form of eye cancer. MyUvealMelanoma tells the story of this disease, its treatment and the importance of prognostic testing, through the experience of patients who recently faced this devastating diagnosis first-hand.

15 Feb 2013

Ingenuity Systems receives HIPAA Certification

Ingenuity Systems, a leading provider of biomedical information and analysis solutions, today announced that it has passed the Health Insurance Portability and Accountability Act (HIPAA) audit, confirming that Ingenuity's data center and Ingenuity Variant Analysis are in compliance with relevant Federal Regulations.

15 Feb 2013

SQI Diagnostics reports net loss of $1,563,000 for quarter-ended December 31, 2012

SQI Diagnostics Inc., a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced its financial and operational results for the first quarter-ended December 31, 2012.

15 Feb 2013

Theradiag’s new biotherapy monitoring kits receive CE mark approval

Theradiag, a company specializing in theranostic and in vitro diagnostics, today announced it has obtained a CE mark for two new biotherapy monitoring kits; Tocilizumab (anti-IL6R) and Rituximab (anti-CD20) that further expand the Lisa Tracker range.

14 Feb 2013

TP PCR methodology may help streamline genetic testing for Huntington's

A new test may help to streamline genetic testing for Huntington Disease (HD) by generating accurate results, avoiding unnecessary additional testing, and improving turnaround time.

14 Feb 2013

HRI to begin enrollment in RAD001 Phase II trial for Neurofibromatosis Type-2

House Research Institute (HRI) is recruiting patients for a Phase II clinical trial to test a medication that may slow the progression of Neurofibromatosis Type-2, commonly referred to as NF2.

13 Feb 2013

Valor, Oxygen Biotherapeutics enter License and Supply Agreement for Dermacyte

Oxygen Biotherapeutics, Inc., announced today that it has entered into a License and Supply Agreement with the Cosmetics Division of Valor SA of Lausanne, Switzerland, for Dermacyte, a perfluorocarbon based cosmetic product currently manufactured and distributed by Oxygen Biotherapeutics.

11 Feb 2013

U.S. adults with diabetes report increased satisfaction with Roche's ACCU-CHEK products

Adults living with diabetes in the United States reported highest satisfaction using Roche Diabetes Care's ACCU-CHEK products compared with other blood glucose meter manufacturers, according to the inaugural J.D. Power and Associates 2012 Blood Glucose Meter Satisfaction Study.

6 Feb 2013

Viracor-IBT Laboratories signs definitive agreement to purchase assets of Cylex

Viracor-IBT Laboratories, Inc. announced today that it has signed a definitive agreement to purchase the assets of Cylex, Inc., a global life sciences company focused on the development, manufacturing and commercialization of in vitro diagnostic products intended to illuminate immunity in the area of transplant medicine.

5 Feb 2013

BD first quarter revenues increase 3.7% to $1.90 billion

BD, a leading global medical technology company, today reported quarterly revenues of $1.90 billion for the first fiscal quarter ended December 31, 2012, representing an increase of 3.7 percent from the prior-year period, or 5.2 percent on a foreign currency-neutral basis.

From BD (Becton, Dickinson and Company) 5 Feb 2013

ATI Neurostimulation System demonstrates clinical effectiveness in treating cluster headache

Autonomic Technologies, Inc. (ATI), the developer of the ATI Neurostimulation System designed for the treatment of severe headaches, today announced results of their clinical study in cluster headache, now published online in Cephalalgia.

5 Feb 2013

Maimonides, Navidea to evaluate Lymphoseek use in lymphatic mapping for colorectal cancer

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced it has entered into an agreement to collaborate with Maimonides Medical Center to investigate the utility of Lymphoseek (technetium Tc 99m tilmanocept) Injection in lymphatic mapping procedures for colorectal cancer.

5 Feb 2013

Technion, Alpha Szenszor partner to commercialize lung cancer diagnostics

Alpha Szenszor Inc., a leading provider of carbon nanotube based sensors and the Technion -Israel Institute of Technology have announced a joint venture for the commercialization of advanced lung cancer diagnostics based on Volatile Organic Compound (VOC) detection from human breath.

5 Feb 2013

Agilent launches new application compendiums on designer drug testing and toxicology of oral fluids

Agilent Technologies Inc. today introduced new application compendiums on designer drug testing and toxicology of oral fluids.

5 Feb 2013

Luminex consolidated fourth quarter revenue increases 16% to $55.5 million

Luminex Corporation today announced financial results for the fourth quarter and year ended December 31, 2012.

From Luminex 4 Feb 2013

Life Technologies full year 2012 revenue increases 2% to $3.8 billion

Life Technologies Corporation today announced results for its fourth quarter for the year ended Dec. 31, 2012.

4 Feb 2013

New method for detecting cancer by measuring elasticity of tumours

As the first countries in the world, Norway and France will be testing a completely new method for detecting cancer. This is done by measuring the elasticity of tumours. The method is called elastography. You may as well learn this new word right away; in a few years, elastography may be as common as X-rays.

4 Feb 2013